| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 |
|---|---|---|---|---|---|---|---|---|---|
Operating activities: | |||||||||
Net income (loss) | |||||||||
-48,169 | -49,048 | -613 | -74,874 | -50,122 | -99 | -3,887 | - | -5,457 | -319 |
Loss from continuing operations | |||||||||
- | - | - | - | - | - | - | -7,631 | - | - |
Loss from discontinued operations | |||||||||
- | - | - | - | - | - | - | -333 | - | - |
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | |||||||||
Deferred income taxes | |||||||||
- | - | - | - | - | - | - | - | 3 | 0 |
Bad debt expense | |||||||||
- | - | - | - | - | - | - | - | 326 | 554 |
Depreciation and amortization expense | |||||||||
98 | 50 | 101 | 201 | 192 | 199 | 236 | 138 | 531 | 432 |
Amortization of right of use assets | |||||||||
156 | - | - | - | - | - | - | - | - | - |
Stock-based compensation | |||||||||
351 | 562 | 614 | 548 | 2,934 | 38 | 55 | 120 | 0 | - |
Interest expense, net | |||||||||
- | 58 | - | - | - | - | - | - | - | - |
Loss on impairment goodwill | |||||||||
46,103 | - | - | - | - | - | - | - | - | - |
Loss on impairment of in process research and development | |||||||||
- | -53,905 | - | - | - | - | - | - | - | - |
Gain on settlement of mortgage note receivable | |||||||||
- | -106 | - | - | - | - | - | - | - | - |
Deferred income tax | |||||||||
- | - | 6,880 | 29,413 | 15,267 | -52 | 0 | - | - | - |
Loss on return of escrowed shares | |||||||||
- | - | 0 | 0 | -1,686 | -584 | 0 | 0 | - | - |
Impairment loss on mortgage note receivable | |||||||||
- | - | 0 | -1,177 | 0 | - | - | - | - | - |
Impairment on IPR&D | |||||||||
- | - | 0 | 92,396 | 38,665 | 0 | - | - | - | - |
Realized gain on sale of marketable securities | |||||||||
- | - | - | - | - | 1,359 | 0 | - | - | - |
Impairment on IPR&D | |||||||||
- | - | - | - | - | 0 | - | - | - | - |
Loss on disposal of property and equipment | |||||||||
- | -60 | -100 | 0 | 0 | 6 | 0 | - | - | - |
Payments on operating lease liabilities | |||||||||
133 | - | - | - | - | - | - | - | - | - |
Fair value of warrant liabilities in excess of proceeds from financing | |||||||||
- | - | - | - | - | - | 0 | - | - | - |
Amortization of financing costs | |||||||||
- | - | - | - | - | - | - | 36 | 160 | 7 |
Write-off obsolete inventory | |||||||||
- | - | - | - | - | - | - | - | 1,439 | 0 |
Change in fair value of derivative liabilities | |||||||||
256 | 306 | 907 | 2,603 | -9,916 | -5,730 | 192 | 153 | -281 | 0 |
Gain on settlement of mortgage note receivable | |||||||||
- | 106 | - | - | - | - | - | - | - | - |
Deferred income tax benefit | |||||||||
- | 13,582 | - | - | - | - | - | - | - | - |
Change in deferred rent | |||||||||
- | - | - | - | - | 0 | - | - | - | - |
Equity in loss of unconsolidated subsidiary | |||||||||
- | - | - | - | - | - | - | - | -42 | - |
Equity interest in subsidiary | |||||||||
- | - | - | - | - | - | - | - | - | -55 |
Non-cash interest expense | |||||||||
- | - | - | - | - | - | - | 5,181 | 758 | 0 |
Changes in operating assets and liabilities: | |||||||||
Accounts receivable | |||||||||
644 | - | -20 | -11 | 0 | 0 | - | - | 560 | -650 |
Inventories | |||||||||
- | - | - | - | - | - | - | - | -665 | -62 |
Prepaid expenses and other current assets | |||||||||
-22 | 86 | -413 | 76 | 212 | 9 | -1 | - | -102 | 43 |
Deposits | |||||||||
-10 | -9 | - | - | - | -3 | - | - | - | - |
Accounts payable and accrued expenses | |||||||||
919 | 240 | 281 | -2,022 | 1,891 | -551 | 103 | - | - | - |
Deferred rent | |||||||||
- | 28 | 32 | -2 | 0 | - | - | - | - | - |
Deferred taxes | |||||||||
- | - | - | - | - | - | - | - | - | -103 |
Accounts payable | |||||||||
- | - | - | - | - | - | - | - | 652 | -58 |
Accrued expenses and other current liabilities | |||||||||
- | - | - | - | - | - | - | -80 | 1,047 | -49 |
Net cash used in operating activities - continuing operations | |||||||||
- | - | - | - | - | - | - | -2,722 | -420 | -261 |
Net cash used in operating activities - discontinued operations | |||||||||
- | - | - | - | - | - | - | 1,133 | - | - |
Net cash (used in) provided by operating activities | |||||||||
-1,563 | -8,290 | -6,903 | -14,655 | -10,317 | -6,012 | -3,686 | -1,588 | - | - |
Investing activities: | |||||||||
Cash acquired in acquisition of Biozone Pharmaceuticals, Inc. | |||||||||
- | - | - | - | - | 589 | 0 | - | 585 | 0 |
Cash acquired in acquisition of RFS Pharma, Inc. | |||||||||
- | - | - | - | - | 194 | 0 | - | - | - |
Purchases of property and equipment | |||||||||
145 | 28 | 40 | 51 | 339 | 5 | 4 | 152 | 575 | 357 |
Proceeds from sale of marketable securities | |||||||||
- | - | - | - | - | 7,900 | 0 | - | - | - |
Investment in mortgage note receivable | |||||||||
- | - | - | - | - | 2,626 | 0 | - | - | - |
Long-term deposits | |||||||||
- | - | - | - | - | - | 0 | - | - | - |
Proceeds from settlement of mortgage note receivable | |||||||||
- | 1,400 | 0 | 33 | 0 | 0 | - | - | - | - |
Principal payments received on mortgage note receivable | |||||||||
- | - | 0 | -21 | -77 | -30 | 0 | - | - | - |
Net cash used in investing activities | |||||||||
-145 | 1,372 | -40 | 3 | -262 | 6,082 | -4 | -152 | 10 | -357 |
Financing activities: | |||||||||
Payments on finance lease liabilities | |||||||||
214 | 19 | - | - | - | - | - | - | - | - |
Repayment of borrowings from noteholders | |||||||||
- | - | - | - | - | - | - | 2,650 | 2,725 | 92 |
Payment of deferred financing costs | |||||||||
- | - | - | - | - | - | - | 36 | 150 | 0 |
Proceeds from sale of common stock, net of transaction costs | |||||||||
6,638 | 7,684 | 3,000 | 9,013 | 15,862 | - | - | 650 | 705 | 0 |
Proceeds from issuance of convertible notes | |||||||||
- | 1,000 | 1,000 | 0 | 0 | - | - | 3,750 | 2,750 | 0 |
Proceeds from exercise of stock options | |||||||||
- | 228 | 80 | 3 | 23 | 116 | 7 | - | - | - |
Proceeds from issuance of common stock and warrants | |||||||||
- | - | - | - | - | 2,750 | 0 | - | - | - |
Repayment of debt | |||||||||
- | - | - | - | - | - | - | - | 0 | - |
Advance from (payment to) shareholder | |||||||||
- | - | - | - | - | - | - | - | 3 | - |
Advance from (payment to) shareholder | |||||||||
- | - | - | - | - | - | - | - | - | 375 |
Net cash provided by financing activities | |||||||||
6,424 | 8,893 | 4,080 | 9,016 | 15,885 | 2,866 | 7 | 1,713 | 575 | 283 |
Net increase in cash and restricted cash | |||||||||
4,716 | 1,975 | -2,863 | -5,636 | 5,306 | - | - | - | - | - |
SUPPLEMENTAL DISCLOSURE OF NON-CASH OPERATING ACTIVITIES: | |||||||||
Purchases of property and equipment under capital leases | |||||||||
- | 347 | - | - | - | - | - | - | - | - |
Recognition of operating lease right-of-use assets and operating lease liabilities upon adoption of ASC Topic 842, Leases | |||||||||
833 | - | - | - | - | - | - | - | - | - |
Issuance of commons stock upon conversion of notes payable | |||||||||
- | 2,062 | - | - | - | - | - | - | - | - |
Net decrease in cash and cash equivalents | |||||||||
- | - | - | - | - | 2,936 | -3,683 | -27 | 164 | -335 |
Cashless exercise of warrants | |||||||||
- | - | 0 | 35 | 14,265 | 0 | - | - | - | - |
Unrealized gain on marketable securities, net of tax | |||||||||
- | - | - | - | - | 236 | 0 | - | - | - |
Purchases of property and equipment under capital leases | |||||||||
- | - | - | - | - | - | 0 | - | - | - |
Prepaid expenses and other current assets | |||||||||
- | - | - | - | - | 5 | 0 | - | - | - |
Marketable securities | |||||||||
- | - | - | - | - | 8,811 | 0 | - | - | - |
Accounts payable and accrued expenses | |||||||||
- | - | - | - | - | -410 | 0 | - | - | - |
Derivative liabilities | |||||||||
- | - | - | - | - | -10,475 | 0 | - | - | - |
Fair value of Series A preferred stock issued in acquisition of RFS Pharma, LLC | |||||||||
- | - | - | - | - | 178,218 | 0 | - | - | - |
Fair value of stock options issued in acquisition of RFS Pharma, LLC | |||||||||
- | - | - | - | - | 6,566 | 0 | - | - | - |
Fair value of assets acquired and liabilities assumed in acquisition of RFS Pharma, LLC | |||||||||
- | - | - | - | - | - | 0 | - | - | - |
In-process research and development | |||||||||
- | - | - | - | - | 184,966 | 0 | - | - | - |
Goodwill | |||||||||
- | - | - | - | - | 65,195 | 0 | - | - | - |
Deferred tax liabilities | |||||||||
- | - | - | - | - | -65,195 | 0 | - | - | - |
Prepaid expenses and other current assets | |||||||||
- | - | - | - | - | 132 | - | - | - | - |
Accounts payable and accrued expenses | |||||||||
- | - | - | - | - | -532 | - | - | - | - |
Property and equipment | |||||||||
- | - | - | - | - | 14 | 0 | - | - | - |
Other long term assets | |||||||||
- | - | - | - | - | 10 | 0 | - | - | - |
Interest paid | |||||||||
- | - | - | - | - | - | - | 256 | 539 | 439 |
Issuance of commons stock upon exchange of convertible notes payable, including accrued interest | |||||||||
- | - | - | - | - | - | - | - | 509 | 0 |
Derivative liability relieved for cashless exercise of warrant for common stock | |||||||||
- | - | - | - | - | - | - | - | 0 | - |
Debt discount from warrant liability | |||||||||
- | - | - | - | - | - | - | 2,755 | 0 | - |
Deemed dividend on preferred stock | |||||||||
- | - | - | - | - | - | - | 0 | - | - |